NCT07902817
A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Trial sites expanded: 0 → 4 locations
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
To evaluate the effect of JADE101 on Urine Protein Creatinine Ratio (UPCR) in participants with IgA nephropathy
Timeframe: Week 52
Secondary (1)
To evaluate the effect of JADE101 on Estimated Glomerular Filtration Rate (eGFR) in participants with IgA nephropathy
Arms and interventions
JADE101 Q8WExperimental
Subcutaneous (SC) injection of JADE101 with Q8W maintenance dosing
JADE101 Q12WExperimental
Subcutaneous (SC) injection of JADE101 with Q12W maintenance dosing
PlaceboPlacebo comparator
Subcutaneous (SC) injection of placebo during the placebo-controlled treatment period
Drugs: JADE101, Placebo
Sites
4 sites in 1 country